News

Filter

Current filters:

EsbrietPharmaceutical

1 to 9 of 14 results

Roche makes another acquisition, paying $8.3 billion for InterMune

Roche makes another acquisition, paying $8.3 billion for InterMune

25-08-2014

Announcing its fourth acquisition this year, Swiss pharma major Roche said on Sunday that it has entered…

EsbrietInterMuneMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoche

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK pharma group slams NICE for failing to recognize nature of discovery and development

07-12-2012

The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…

EsbrietEuropeInterMunePharmaceuticalPricingRegulation

French price regulator authorizes reimbursement of InterMune's Esbriet

12-09-2012

USA-based InterMune (Nasdaq: ITMN) says that French regulator the Comite Economique des Produits de…

EsbrietEuropeInterMunePharmaceuticalPricingRespiratory and Pulmonary

French Transparency Commission issues favorable opinion on Esbriet

10-04-2012

There was good news last week for USA-based InterMune (Nasdaq: ITMN) when the Transparency Commission…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Esbriet offers additional benefit, says German G-BA

16-03-2012

USA-based InterMune (Nasdaq: ITMN) says that the German Federal Joint Committee (G-BA) has announced…

EsbrietEuropeInterMunePharmaceuticalPricingRegulationRespiratory and Pulmonary

Longer-term safety profile of InterMune’s Esbriet in IPF demonstrated; Call for greater awareness of PF

26-09-2011

US biotech firm InterMune (Nasdaq: ITMN) has reported that new data at the European Respiratory Society…

BiotechnologyCardio-vascularEsbrietHealthcareInterMunePharmaceuticalResearchRespiratory and Pulmonary

1 to 9 of 14 results

Back to top